Your search for osteoporosis returned 10 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

News remove
Drugs in the Pipeline remove

Your search for osteoporosis returned 10 results

Sort Results:

Relevant Recent
Drugs in the Pipeline

Phase 3 Study of Ostora for Postmenopausal Osteoporosis

Unigene Laboratories, Inc. and its licensee Tarsa Therapeutics announced positive results from its Phase 3 study of Ostora in 565 postmenopausal women for the treatment of postmenopausal osteoporosis.
Drugs in the Pipeline

NDA Accepted for EX101 for Osteoporosis

EffRx Pharmaceuticals announced the FDA has accepted its New Drug Application (NDA) for the company's lead development program EX101.
Drugs in the Pipeline

Phase 2 results of ZP-PTH for osteoporosis

Zosano Pharma announced that an abstract detailing results of its Phase 2 study of ZP-PTH for the treatment of established osteoporosis will be presented as a poster at the 8th International Symposium on Osteoporosis in Washington D.C.
Drugs in the Pipeline

Phase 3 study of arzoxifene for osteoporosis

Eli Lilly presented new phase 3 clinical trial data showing arzoxifene, an investigational selective estrogen receptor modulator (SERM), was superior to Evista (raloxifene) at increasing bone mineral density (BMD) in the lumbar spine, total hip and femoral neck, and at suppressing bone turnover as assessed by serum markers of bone metabolism.